AbCellera Biologics Inc. ABCL Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -289%+803pp | -1,091.6%-468pp | -623.8%— | —— | |
| Net margin | -194.9%+370pp | -564.8%-180pp | -385%— | —— | |
| Returns | |||||
| Return on equity | -14.5%+0.3pp | -14.7%-2.5pp | -12.3%— | —— | |
| Return on invested capital | -22.3%+8.2pp | -30.5%-7.1pp | -23.4%— | —— | |
| Efficiency | |||||
| Asset turnover | 0.1×0.0× | 0×0.0× | 0×-0.3× | 0.3×0.0× | |
| Liquidity | |||||
| Current ratio | 11.3×+1.5× | 9.8×+2.5× | 7.3×-1.3× | 8.7×+1.0× | |
| Leverage | |||||
| Debt-to-equity | 0.1×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $3.24-9.8% | $3.59-10.0% | $3.99+1.7% | $3.92+21.6% | |
| Valuation | |||||
| Market capitalization | $1.02B+18.3% | $865.42M-47.8% | $1.66B-42.8% | $2.9B-28.0% | |
| Price / sales | 13.6×-16.4× | 30×-13.6× | 43.6×+37.6× | 6×-4.8× | |
| Price / book | 1.1×+0.2× | 0.8×-0.6× | 1.4×-0.9× | 2.4×-1.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do AbCellera Biologics Inc.'s ratios come from?
- Every ratio is computed from AbCellera Biologics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
